Search #ABSTRACT#
Dey, L.P. Granted Patent for DuoNeb®, COPD Medication
Napa, CA, October 29, 2003 - Dey L.P., a specialty pharmaceutical company focused on prescription drug products for the treatment of selected respiratory diseases and allergies, has announced that effective October 14, 2003, the U.S. Patent and Trademark Office (USPTO) has issued a patent covering DuoNeb. DuoNeb is the only FDA-approved unit-dose combination inhalation therapy of albuterol sulfate and ipratropium bromide for the treatment of chronic obstructive pulmonary disease (COPD). DuoNeb was developed by Dey, L.P.
“The USPTO’s granting of this patent for DuoNeb is a significant event for Dey,” said J. Melville Engle, President and Chief Executive Officer of Dey, L.P. “DuoNeb delivers a unique combination of nebulized inhalation therapy which simplifies the daily treatment regimen for many COPD patients.“
About Dey, L.P.
Dey, L.P., is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases and respiratory-related allergies. Since 1978, patients have benefited from Dey’s commitment to innovative and affordable health care solutions.The Web sites for DEY include www.dey.com, www.accuneb.com, www.curosurfusa.com, www.duoneb.com and www.epipen.com. Dey is an affiliate of EMD, Inc., a division of Merck KGaA, Darmstadt, Germany.
###
Contact: Dey, L.P. Media Line 1-800-755-5560 ext. 8363
